Article Text

Download PDFPDF
Serum peroxiredoxin 3 is reduced in genetic carriers of Parkinson’s disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • ASN and JT are joint first authors.

  • LCT and EKT are joint senior authors.

  • Contributors AN and YT contributed equally to this paper. Conception and design: AN, YT and EKT. Acquisition of data: YT, EN, KYT, WLA, LT and EKT. Analysis and interpretation of data: AN and YT. Writing of the first draft: AN and YT. Review and critique: EKT. Reviewed manuscript: all authors.

  • Funding This study was funded by Singapore’s National Medical Research Council (AN by the Clinician-Scientist New Investigator Grant (CNIG/1165/2017) and Transition Award (MOH-TA18may-0003); EKT and LT by the Parkinson’s disease Translational and Clinical Research flagship grant (TCR12dec010), Open Fund Large Collaborative Grant (MOH-OFLCG18May-0002), and Singapore Translational Research (STaR) Investigator award (NMRC/STaR/014/2013)). Part of the data and biospecimens used in this study were obtained from the MJFF LCC, which is coordinated and funded by the Michael J Fox Foundation for Parkinson’s disease research. For up-to-date information on the LCC study, visit https://www.michaeljfox.org/page.html?lrrk2-cohort-consortium.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.